Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 1, 2000, Pages 57-62

  Westermann, Anneke M ^a,b   Dubbelman, Ria ^a   Baars, Jan P ^a   Moolenaar, Wouter H ^a   Beijnen, Jos H ^a   Rodenhuis, Sjoerd ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Ascites; Lysophosphatidic acid; Mesothelioma; Ovarian cancer; Suramin

Indexed keywords

GROWTH FACTOR; LYSOPHOSPHATIDIC ACID; SURAMIN;

ABDOMINAL CANCER; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; OVARY CARCINOMA; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0033934581     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000116     Document Type: Article

References (33)

1. 1. Xu Y, Mills GB (1995) Activation of human ovarian cancer cells: role of lipid factors in ascitic fluid. In: Sharp F, Mason P, Blackett T, Berek J (eds) Ovarian cancer 3. Chapman & Hall, London, p 121
2. 2. Van Corven EJ, Groenink A, Jalink K, Eichholtz T, Moolenaar WH (1989) Lysophosphatidate-induced cell proliferation: identification and dissection of signalling pathways mediated by G proteins. Cell 59: 45
3. 3. Imamura F, Horai T, Mukai M, Shinkai K, Sawada M, Akedo H (1993) Induction of in vitro tumor cell invasion of cellular monolayers by lysophosphatidic acid or phospholipase D. Biochem Biophys Res Commun 193: 497
4. 4. Moolenaar WH, Kranenburg O, Postma FR, Zondag GCM (1997) Lysophosphatidic acid: G-protein signalling and cellular responses. Curr Opin Cell Biol 9: 168
5. 5. Stam JC, Michiels F, Van der Kammen RA, Moolenaar WH, Collard JG (1998) Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signalling. EMBO J 17: 4066
6. 6. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G (1998) Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 280: 719
7. 7. Westermann AM, Havik E, Postma FR, Beijnen JH, Dalesio O, Moolenaar WH, Rodenhuis S (1998) Malignant effusions contain LPA-like activity. Ann Oncol 9: 437
8. 8. Van Corven EJ, Van Rijswijk A, Jalink K, Van der Bend RL, Van Blitterswijk WJ, Moolenaar WH (1992) Mitogenic action of lysophosphatidic acid and phosphatidic acid. Dependence on acyl chain length and inhibition by suramin. Biochem J 281: 163
9. 9. Stein CA (1993) Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 53: 2239
10. 10. Rosen PJ, Mendoza EF, Landaw EM, Mondino B, Graves MC, McBride JH, Turcillo P, deKernion J, Belldegrun A (1996) Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy. J Clin Oncol 14: 1626
11. 11. Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodcell DI, Zuhowski EG, Tkaczuk KH, Lowitt MH, Hemady RK, Jacobs SC (1995) Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer. J Clin Oncol 13: 2174
12. 12. Garcia-Schurmann JM, Schulze H, Haupt G, Pastor J, Allolio B, Senge T (1999) Suramin treatment in hormone-and chemotherapy-refractory prostate cancer. Urology 53: 535
13. 13. La Rocca RV, Cooper MR, Stein CA, Kohler D, Uhrich M, Weinberger E, Myers CE (1992) A pilot study of suramin in the treatment of progressive refractory follicular lymphomas. Ann Oncol 3: 571
14. 14. Hutson PR, Tutsch KD, Rago R, Arzoomanian R, Alberti D, Pomplun M, Church D, Marnocha R, Cheng AL, Kehrli N, Wilding G (1998) Renal clearance, tissue distribution, and CA-125 responses in a phase I trial of suramin. Clin Cancer Res 4: 1429
15. 15. Ozols RF, Gore M, Tropé C, Grenman S (1999) Intraperitoneal treatment and dose-intense therapy in ovarian cancer. Ann Oncol 10 [Suppl 1]: S59
16. 16. Markman M (1998) Intraperitoneal therapy of ovarian cancer. Semin Oncol 25: 356
17. 17. De Graaf PW, Mellema MM, ten Bokkel Huinink WW, Aartsen EJ, Dubbelman R, Franklin HR, Hart AA (1988) Complications of Tenckhoff catheter implantation in patients with multiple previous intraabdominal procedures for ovarian carcinoma. Gynecol Oncol 29: 43
18. 18. Beijnen JH, Gijn R van, Clippeleir JJ de, Vlasveld LTh, Horenblas S, Underberg WJM (1990) Rapid determination of suramin in micro-volumes of plasma by using ion-pair high performance liquid chromatography. J Drug Dev 3: 21
19. 19. Westermann AM, Dubbelman R, Moolenaar WH, Beijnen J, Rodenhuis S (1997) Successful intraperitoneal suramin treatment of peritoneal mesothelioma. Ann Oncol 8: 801
20. 20. Chaudry V, Eisenberger MA, Sinibaldi VJ, Sheikh H, Griffin JW, Cornblath DR (1996) A prospective study of suramin-induced peripheral neuropathy. Brain 119 (Pt 6): 2039
21. 21. Britton RJ, Figg WD, Venzon DJ, Dalakas MC, Bowden C, Headlee D, Reed E, Myers CE, Cooper MR (1995) Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin. J Clin Oncol 13: 2223
22. 22. Kobayashi K, Weiss RE, Vogelzang NJ, Yokes EE, Janisch L, Ratain MJ (1996) Mineralocorticoid insufficiency due to suramin therapy. Cancer 78: 2411
23. 23. Hemady K, Sinibaldi VJ, Eisenberger MA (1996) Ocular symptoms and signs associated with suramin sodium treatment for metastatic cancer of the prostate. Am J Ophthalmol 121: 291
24. 24. Lowitt MH, Eisenberger M, Sina B, Kao GF (1995) Cutaneous eruptions from suramin. A clinical and histopathologic study of 60 patients. Arch Dermatol 131: 1147
25. 25. Dawson NA, Lush RM, Steinberg SM, Tompkins AC, Headlee DJ, Figg WD (1996) Suramin-induced neutropenia. Eur J Cancer 32A: 1534
26. 26. Tisdale JF, Figg WD, Reed E, McNall NA, Alkins BR, Horne MK 3rd (1996) Severe thrombocytopenia in patients treated with suramin: evidence for an immune mechanism in one. Am J Hematol 51: 152
27. 27. Smith A, Harbour D, Liebmann J (1997) Acute renal failure in a patient receiving treatment with suramin. Am J Clin Oncol 20: 433
28. 28. Scher H, Jodrell D, Iversen J, Curley T, Tong W, Egorin M, Forrest A (1992) Use of adaptive control with feedback to individualize suramin dosing. Cancer Res 52: 64
29. 29. Eisenberger MA, Reyno LM (1994) Suramin (review). Cancer Treat Rev 20: 259
30. 30. Kobayashi K, Vokes EE, Vogelzang NJ, Janish L, Soliven B, Ratain MJ (1995) Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13: 2196
31. 31. Reyno LM, Egorin MJ, Eisenberger MA, Sinibaldi VJ, Zuhowski EG, Sridhara R (1995) Development and validation of a pharmacokinetically based fixed dosing schedule for suramin. J Clin Oncol 13: 2187
32. 32. Beijnen JH, Van Gijn R, Horenblas S, Underberg WJM (1990) Chemical stability of suramin in commonly used infusion fluids. Drug Intell Clin Pharm 24: 1056
33. 33. Collins J, Klecker R, Yarchoan R, Lane H, Fauci A, Redfield R, Broder S, Myers C (1986) Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 26: 22